Tactile Systems Technology (NASDAQ:TCMD) Releases Earnings Results, Beats Estimates By $0.09 EPS

Tactile Systems Technology (NASDAQ:TCMD) released its earnings results on Tuesday. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.09, Zacks reports. Tactile Systems Technology had a return on equity of 9.24% and a net margin of 5.42%. Tactile Systems Technology updated its FY 2025 guidance to EPS.

Tactile Systems Technology Price Performance

Tactile Systems Technology stock opened at $17.86 on Wednesday. The stock’s 50 day moving average is $17.45 and its 200 day moving average is $15.61. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.37 and a quick ratio of 3.80. The firm has a market cap of $428.64 million, a P/E ratio of 27.48 and a beta of 1.20. Tactile Systems Technology has a one year low of $11.12 and a one year high of $21.10.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. StockNews.com cut Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 16th. BTIG Research cut Tactile Systems Technology from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 5th. Oppenheimer cut Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. Finally, B. Riley lowered Tactile Systems Technology from a “buy” rating to a “neutral” rating and cut their price target for the company from $23.00 to $18.00 in a research note on Wednesday.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.